Mangalam Drugs and _Organics Ltd. A Regd. Office: Rupam Building, 3rd Floor, 239 P. D'Mello Roc.1d , Near G. P. 0. Mumbai - 400 001. Phone: 91-22-22616200 / 6300 / 8787 • Fax : 91 -22-22619090 • CIN : L24230MH1972PLC116413 ..._,. ---------------------------- ~ To, Corporate Relation Department BSE Ltd 1 st Floor, New Trade Wing, Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 00 I. Scrip Code: 532637 09 th May, 2019 National Stock Exchange of India Limited · "Exchange Plaza", C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 05 Symbol: MANGALAM Sub: Audited Financial Results for the Quarter and year ended on 31 st March, 2019 Dear Sir, 111 terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith Audited Financial Results for the quarter and year ended 31st March, 2019 along with Auditors Report and the statement of Assets and Liabilities as at the year ended on March 31 , 20 I 9 in the prescribed format which have been taken on record and approved by the Board of Directors of the company in its meeting held today i.e. 09 th May, 2019 at Mumbai. Kindly note that meeting of Board of Directors commenced at 4.00 P.M. and concluded at 5.35 P.M. Further please note that the company has made necessary arrangement to publish the same in newspapers as required under Listing Regulations. Kindly acknowledge the receipt and take the same on your records. m• f~ , 1it1ltl 0 13 .. ISO 9001- 2008 Accredited Comoanv WHO-GMP I Certified Works : at Va pi (Guj arat) India • E-Mail : contactu s@mangalamdrugs.com • Website : http://www.mangalamdrugs.com
Transcript
Mangalam Drugs and_Organics Ltd. A Regd. Office: Rupam Building, 3rd Floor, 239 P. D'Mello Roc.1d , Near G. P. 0. Mumbai - 400 001. ~
Notes: 1 The above results have been prepared in accordance with Indian Accounting Standard (Ind AS) notified under section 133 of the companies Act 2013, read
together with Companies (Indian Accounting Standard) Rules, 2015.
2 The above results have been reviewed by the Audit Committee and thereafter, were approved & taken on record by the Board of Directors of the Company at their meeting held on May 9, 2019. The Statutory Auditors have expressed an unmodified audit opinion on these financial result.
3 As the Company's business activity falls within a single primary Business Segment Viz. "Manufacturing of Bulk Drugs" and hence does not have any additional disclosure to be made under Ind AS-108 on "Operating Segments".
4 Figures for the quarters ended 31st March 2019 and 31st March 2018 are the balancing figures between audited figures for the full financial year and the reviewed year to date figures upto the third quarter of the respective financial years.
5 The company has incurred loss during the year due to certain unforeseen circumstances & the major reason being delay in finalisation of tenders for malaria drugs by international regulatories. However we are confident of improved results in subsequent quarters once these procurements are streamlined by them shortly.
6 Earlier period figures have been regrouped/ rearranged wherever necessary.
Place:Mumbai Date: 09th May, 2019
•
Statement of Assets and Liabilities Rs. in Lacs Rs. in Lacs
As at 31.03.2019 As at 31.03.2018 Audited Audited
ASSETS A. Non-current Assets (a) Property, Plant and Equipment 10077.78 10115.60
(d) Financial Assets (i) Investments 24.01 24.01 (ii) Other Financial Assets 178.37 172.53
(iii) Defered Tax Asset (Net)
(e) Non Current Tax Assets (Net) (f) Other Non-current Assets 60.01 0.00
Total Non-current Assets (A) 10408.65 10,394.58
B. Current Assets (a) Inventories 7345.32 6013.42 (b) Financial Assets
(i) Trade Receivables 1763.07 4520.77 (ii) Cash and Cash Equivalents 143.34 43.03 (iii) Bank Balance other than Cash and Cash Equivalents (iv) Loans 0.88 1.25
(v) Others Financial Assets (c) Other Current Assets 1251.36 1705.69
Total Current Assets (B) 10503.97 12,284.17
TOTAL ASSETS 20912.61 22,678.74
EQUITY AND LIABILITIES A. Equity (a) Equity Share Capital 1582.82 1582.82 (b) Other Equity 7992.80 8793.83
Total Equity (A) 9575.62 10,376.66
B. Non-Current Liability (a) Financial Liabilities
Auditor's Report on Quarterly Financial Results and Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015.
TO THE BOARD OF DIRECTORS OF MANGALAM DRUGS & ORGANICS LIMITED
We have audited the quarterly financial results of MANGALAM DRUGS & ORGANICS LIMITED for the quarter ended 31 st March 2019 and the year to date results for the period 01 st
April 2018to 31 st March 2019, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obiigations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opin:on on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (Ind AS 34)for Interim Financial Reporting, prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.
We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.
In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:
i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard ; and
ii) give a true and fair view of the net loss and other financial information for the quarter ended 31 st March 2019 and the year to date results for the period 01 st April 2018 to 31 st March 2019.
To, Corporate Relation Department BSE Ltd 1st Floor, New Trade Wing, Rotunda Building, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001.
Scrip Code: 532637
09th May, 2019
National Stock Exchange of India Limited "Exchange Plaz2.", C-1, Block G, Bandra - Kurla Complex, Bandra(E), Mumbai - 400 05
Symbol: MANGALAM
Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements), (Amendment) Regulations, 2016 w.r.t Audit Report with
unmodified opinion.
Dear Sir/Madam,
I, Shri Govardhan M Dhoot - Managing Director of Mangalam Drugs & Organics Ltd (CIN: L24230MH1972PLC116413) having its Registered office at Rupam Building, 3rd Floor, 239,
P.D'Mello Road, Near GPO, Mumbai-400001, hereby declare that the Statutory Auditors of the
Company i.e. Batliboi & Purohit, Chartefed Accountants (Firm Registration No. 101048W) have issued an Audit Report with unmodified opinions on Standalone Annual Audited Financial
Results for the Year ended 31st March, 2019.
This declaration is given pursuant to Regulation 33(3)(d) of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015, as amended by the SEBI (Listing Obligations and
Disclosure Requirements) (Amendment) Regulations, 2016 vide Circular no.
CIR/CFD/CMD/56/2016 dated May 27, 2016.
Thanking you,
Managing Director ~==~N:01240086 mm lim-013
ISO 9001- 2008 Accredited Com an
W HO-GM P certified Works : at Vapi (Gujarat) India • E-Mail : [email protected] • Website : http://www.mangalamdrugs.com
